

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/163978 A2

- (51) **International Patent Classification:**
C07K 16/244 (2006.01) *A61K 2039/54* (2006.01)
A61K 2039/507 (2006.01) *A61K 2039/545* (2006.01)
- (21) **International Application Number:**
PCT/US2024/014361
- (22) **International Filing Date:**
02 February 2024 (02.02.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/483,000 02 February 2023 (02.02.2023) US
63/503,087 18 May 2023 (18.05.2023) US
- (71) **Applicant: MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, MD 20878 (US).
- (72) **Inventor: GRIFFITHS, Janet**; c/o MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 (US).
- (74) **Agent: NEVILLE, Katherine, L.**; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** TREATMENT OF CHRONIC RHINOSINUSITIS WITH ANTI-TSLP ANTIBODY

Figure 1A

Demographic/Characteristic	History of NP (n = 169)		No history of NP (n = 88)	
	All (n = 169)	NP = 2 years before randomization (n = 80)	NP = 2 years before randomization (n = 80)	No history of NP (n = 88)
Age, mean (SD), year	52.3 (11.5)	52.1 (11.7)	53.5 (11.5)	50.3 (11.6)
Female, n (%)	91 (53.8)	42 (52.5)	49 (61.3)	50 (56.8)
Ethnic group, n (%)				
Caucasian	117 (69.2)	57 (71.3)	58 (72.5)	55 (62.5)
African American	27 (16.0)	14 (17.5)	13 (16.3)	14 (15.9)
Hispanic/Latino	12 (7.1)	6 (7.5)	6 (7.5)	6 (6.8)
Asian	4 (2.4)	2 (2.5)	2 (2.5)	2 (2.3)
Other	9 (5.3)	5 (6.3)	5 (6.3)	5 (5.7)
Time since diagnosis, mean (SD), year	10.1 (5.1)	10.2 (5.2)	10.0 (5.0)	10.3 (5.2)
Baseline eosinophil count, n (%)				
< 150/mm ³	107 (63.3)	52 (65.0)	55 (68.8)	55 (62.5)
≥ 150/mm ³	62 (36.7)	28 (35.0)	25 (31.2)	33 (37.5)
Baseline total IgE, mean (SD), IU/mL	107.4 (104.0)	107.2 (114.0)	117.4 (100.8)	107.8 (103.5)
Baseline total IgG, mean (SD), g/L	10.0 (1.5)	10.0 (1.5)	10.0 (1.5)	10.0 (1.5)
Baseline total IgA, mean (SD), g/L	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)
Baseline total IgM, mean (SD), g/L	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)
Baseline eosinophil count, mean (SD), /mm ³	107.4 (104.0)	107.2 (114.0)	117.4 (100.8)	107.8 (103.5)
Baseline total IgE, mean (SD), IU/mL	107.4 (104.0)	107.2 (114.0)	117.4 (100.8)	107.8 (103.5)
Baseline total IgG, mean (SD), g/L	10.0 (1.5)	10.0 (1.5)	10.0 (1.5)	10.0 (1.5)
Baseline total IgA, mean (SD), g/L	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)
Baseline total IgM, mean (SD), g/L	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)	1.0 (0.3)
Baseline eosinophil count, mean (SD), /mm ³	107.4 (104.0)	107.2 (114.0)	117.4 (100.8)	107.8 (103.5)

(57) **Abstract:** The present disclosure, relates, in general, to methods of treating chronic rhinosinusitis, with or without nasal polyps, using an antibody specific for thymic stromal lymphopoietin (TSLP).

WO 2024/163978 A2